The Optimal Use of PEG-asparaginase in Relapsed ALL--lessons from the ALLR3 Clinical Trial

Overview

Journal Blood Cancer J

Date 2014 Apr 29

PMID 24769644

Citations 3

Authors

A Masurekar

C Fong

A Hussein

T Revesz

P M Hoogerbrugge

S Love

C Ciria

C Parker

S Krishnan

V Saha

Affiliations

Soon will be listed here.

Citing Articles

Activity and toxicity of intramuscular 1000 iu/m polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.

Sidhu J, Masurekar A, Gogoi M, Fong C, Ioannou T, Lodhi T Br J Haematol. 2022; 198(1):142-150.

PMID: 35348200 PMC: 9314843. DOI: 10.1111/bjh.18158.

Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia.

Liu J, Masurekar A, Johnson S, Chakraborty S, Griffiths J, Smith D Oncotarget. 2015; 6(40):43048-64.

PMID: 26474278 PMC: 4767490. DOI: 10.18632/oncotarget.5528.

Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.

Ko R, Jones T, Radvinsky D, Robison N, Gaynon P, Panosyan E Cancer. 2015; 121(23):4205-11.

PMID: 26308766 PMC: 4795901. DOI: 10.1002/cncr.29641.

References

Roy A, Cargill A, Love S, Moorman A, Stoneham S, Lim A . Outcome after first relapse in childhood acute lymphoblastic leukaemia - lessons from the United Kingdom R2 trial. Br J Haematol. 2005; 130(1):67-75. DOI: 10.1111/j.1365-2141.2005.05572.x. View

Pieters R, Hunger S, Boos J, Rizzari C, Silverman L, Baruchel A . L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2010; 117(2):238-49. PMC: 3000881. DOI: 10.1002/cncr.25489. View

Willer A, Gerss J, Konig T, Franke D, Kuhnel H, Henze G . Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood. 2011; 118(22):5774-82. DOI: 10.1182/blood-2011-07-367904. View

Boos J, Werber G, Ahlke E, Nowak-Gottl U, Wurthwein G, Verspohl E . Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996; 32A(9):1544-50. DOI: 10.1016/0959-8049(96)00131-1. View

Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman A . Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010; 376(9757):2009-17. PMC: 3010035. DOI: 10.1016/S0140-6736(10)62002-8. View

Messinger Y, Gaynon P, Sposto R, van der Giessen J, Eckroth E, Malvar J . Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 2012; 120(2):285-90. DOI: 10.1182/blood-2012-04-418640. View

Moghrabi A, Levy D, Asselin B, Barr R, Clavell L, Hurwitz C . Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2006; 109(3):896-904. PMC: 1785142. DOI: 10.1182/blood-2006-06-027714. View

Vora A, Goulden N, Wade R, Mitchell C, Hancock J, Hough R . Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol. 2013; 14(3):199-209. DOI: 10.1016/S1470-2045(12)70600-9. View

Tong W, Pieters R, Kaspers G, Loo D, Bierings M, van den Bos C . A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014; 123(13):2026-33. PMC: 3968389. DOI: 10.1182/blood-2013-10-534347. View

10.

Wells R, Feusner J, Devney R, Woods W, Provisor A, Cairo M . Sequential high-dose cytosine arabinoside-asparaginase treatment in advanced childhood leukemia. J Clin Oncol. 1985; 3(7):998-1004. DOI: 10.1200/JCO.1985.3.7.998. View

11.

Samarasinghe S, Dhir S, Slack J, Iyer P, Wade R, Clack R . Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol. 2013; 162(5):710-3. DOI: 10.1111/bjh.12407. View

12.

Yang L, Panetta J, Cai X, Yang W, Pei D, Cheng C . Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol. 2008; 26(12):1932-9. DOI: 10.1200/JCO.2007.13.8404. View

13.

Hawkins D, Park J, Thomson B, Felgenhauer J, Holcenberg J, Panosyan E . Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res. 2004; 10(16):5335-41. DOI: 10.1158/1078-0432.CCR-04-0222. View

14.

Lanvers C, Vieira Pinheiro J, Hempel G, Wuerthwein G, Boos J . Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Anal Biochem. 2002; 309(1):117-26. DOI: 10.1016/s0003-2697(02)00232-4. View

15.

Kelly M, Lu X, Devidas M, Camitta B, Abshire T, Bernstein M . Treatment of relapsed precursor-B acute lymphoblastic leukemia with intensive chemotherapy: POG (Pediatric Oncology Group) study 9411 (SIMAL 9). J Pediatr Hematol Oncol. 2013; 35(7):509-13. PMC: 3957178. DOI: 10.1097/MPH.0b013e31829f3235. View